News and never medical advice

Peptide Zone reports on research, regulation and business news about peptide medicines. Nothing on this site is a recommendation to use, stop or change any treatment, and nothing here replaces a conversation with a qualified clinician who knows your history.

Trial results describe groups of people under trial conditions. They do not predict what will happen to any one person. Approvals and label wording differ between countries and change over time; check the current product information where you live.

We do not publish doses, protocols or places to buy peptides, and we do not answer individual medical questions.

If you think you are having a reaction to a medicine, contact a doctor or pharmacist. In an emergency, call your local emergency number.

Who the wire is for

The wire is written for readers who follow peptide medicine as news: patients and carers who want to understand a headline, clinicians and pharmacists keeping up with agencies, students, analysts and journalists. It assumes no medical training and explains terms the first time they appear.

A story is a snapshot at its filing time. Later events can change what it means, which is why each one carries a story log with its updates. Read the newest entry before relying on an older story, and check the date on the dateline.

What a story can and cannot tell you

A story can tell you what a regulator decided, what a trial reported and what a company announced. It cannot tell you whether a medicine is right for you, whether a product you have seen online is genuine, or what amount to take. Peptides sold as "research use only" are not approved medicines, and nothing on this site should be read as a guide to using them.

How we choose sources and handle mistakes is set out in the standards and corrections policy. To report an error or ask about a story, use the contact form.